Signal transduction

InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

Retrieved on: 
星期三, 七月 5, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Clinical trial, Cancer, Psoriasis, Quality of life, SAD, Signal transduction, BTK, Incidence, SSE, HKEX, Patient, TYK2, MAD, Autoimmunity, Safety, Inflammation, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 in China.
  • The ongoing study with psoriasis patients aims to evaluate the safety and efficacy of ICP-488 in patients with moderate-to-severe psoriasis.
  • ICP-488 is a potent and selective TYK2 allosteric inhibitor, which is developed for the treatment of psoriasis and other autoimmune diseases.
  • InnoCare is developing autoimmune therapeutics with global frontier targets through B-cell and T-cell pathways, including orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor), and more.

EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

Retrieved on: 
星期四, 六月 8, 2023
National Institute on Drug Abuse, Hebrew University of Jerusalem, Al-Quds, Cancer, Quality of life, Research, Signal transduction, Rash, Patient, EGFR, Hadassah Medical Center, NGT, Financial toxicity, Skin, Growth factor, Pharmaceutical industry

JERUSALEM, June 8, 2023 /PRNewswire/ -- Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC.  EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients. Based on over ten years of research collaboration by the founders, Dr. Sharon Merims, a senior dermatologist specializing in dermato-oncology at the Hadassah Medical Center, and Professor Ofra Benny from the Institute for Drug Research at the Hebrew University of Jerusalem, and with the support of NGT Healthcare2 VC, the company's first product aims to treat the skin toxicities caused by EGFRi (Epidermal Growth Factor Receptor inhibitors). Many of the molecularly targeted agents used in current cancer treatments, particularly those interfering with signal transduction EGFRi and small molecule tyrosine kinase inhibitors, are associated with papulopustular skin rash. This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment. Dr. Merims will serve as EMRIS Pharma's Chief Scientific Officer, and Professor Benny as the company's Chief Technology Officer.

Key Points: 
  • EMRIS Pharma is pioneering novel small molecule-based topical compounds that can improve both quality of life and treatment compliance for cancer patients.
  • This rash is observed in ~90% of patients receiving EGFR-targeted monoclonal antibodies, and often impacts the patient's quality of life, and the ability to continue the cancer treatment.
  • Their novel approach to managing skin toxicities caused by EGFR inhibitors has the potential to significantly improve the quality of life for cancer patients and increase treatment compliance.
  • We believe that EMRIS Pharma's innovative research and development will lead to a brighter future for cancer patients, and we look forward to supporting their mission."

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
星期五, 三月 31, 2023
DSM-IV codes, Bevacizumab, COVID-19, Shanghai Stock Exchange, Star Market, European Medicines Agency, XPO1, Ankylosing spondylitis, Patent, Patient, EGFR, ESCC, NPC, R, Spacecraft, FGFR2, Fasting, ATR, Rheumatoid arthritis, Sun, Platinum, Bamlanivimab/etesevimab, Infection, Research, Sun Yat-sen University Cancer Center, SSE, Anaplastic lymphoma kinase, Uveitis, IDH1, Phase, FDA, Pemetrexed, IND, NMPA, Total, CGMP, CD3, Adalimumab, Cancer, Psoriasis, Wujiang, HKEX, Disease, Synergist, PARP, RMB, The New England Journal of Medicine, Acceleration, Nature, Paclitaxel, Targeted therapy, Cisplatin, Respiratory syncytial virus, SHP2, NEJM, Signal transduction, Pharmaceutical industry, Video game, Fine chemical, Vaccine, Medical device

SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB 2,384 million in 2022, representing an increase of approximately 15% compared to 2021.
  • Loss attributable to the owners of the company was RMB 2,386 million in 2022, representing an increase of RMB 1,667 million compared to 2021.
  • In May 2022, the IND application for JS105, a PI3K-α inhibitor jointly developed by Risen (Suzhou) Biosciences Co., Ltd. (“Risen Biosciences”) and the company, was approved by the NMPA.

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
星期三, 四月 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting

Retrieved on: 
星期四, 二月 16, 2023
Trial of the century, Lead, HPV, Cue, Cell signaling, Head, Selective, Nature, Patient, Signal transduction, University, Research, Modes of toxic action, Concept, Poster, Kennedy Institute, Kennedy Institute of Ethics Journal, Vaccine

The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.

Key Points: 
  • The research is part of a strategic research collaboration that Cue Biopharma initiated with Dr. Michael Dustin’s laboratory at the University of Oxford in May 2020 to determine the molecular mechanisms underlying the activity of the company’s interleukin 2 (IL-2) based CUE-100 series of biologics.
  • “The data continue to support the differentiated mechanism of action of Cue Biopharma’s Immuno-STAT CUE-100 series of biologics, by uniquely mimicking the natural process of immune synapse formation,” said Jesusa Capera-Aragones, Ph.D., post-doctoral researcher, Dustin laboratory of the Kennedy Institute at the University of Oxford.
  • “By simultaneously presenting a targeted antigen and the immunostimulatory molecule IL-2, Cue Biopharma’s biologics enable the specific and simultaneous engagement of IL-2 and T cell receptors, as it would occur in nature.
  • Dr. Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, added “We are very pleased with the research and collaboration with Dr. Dustin’s laboratory of the Kennedy Institute at the University of Oxford.

Insilico Medicine Nominates Potential First-in-Class Preclinical Candidate with Novel AI-Designed Structure for Novel AI-Discovered Target in Immuno-oncology

Retrieved on: 
星期二, 十二月 20, 2022
Cancer, DGK, Fibrosis, PD-1, Signal transduction, DGKA, Inflammation, ADME, RNA-Seq, Research, AI, Insilico Medicine, Therapy, IND, DAG, Pharma, Doctor of Philosophy, RNA, Intelligence, Medical device, Pharmaceutical industry, In silico

It is another program fully discovered and designed by AI that Insilico has delivered from target identification to preclinical candidate nomination by leveraging its proprietary end-to-end AI platform, Pharma.AI.

Key Points: 
  • It is another program fully discovered and designed by AI that Insilico has delivered from target identification to preclinical candidate nomination by leveraging its proprietary end-to-end AI platform, Pharma.AI.
  • Immune checkpoint blockade has proven effective in a variety of malignancies, but the response rate of existing therapeutics remains low.
  • The diacylglycerol kinase family (DGKs) is an important player in signal transduction, phosphorylating the membrane lipid, diacylglycerol (DAG), to phosphatidic acid (PA).
  • The preclinical candidate ISM4312A is a potential first-in-class DGKA inhibitor with excellent potency and high selectivity in cancer immunotherapy.

IMIDomics Announces Appointment of Key Science and Medical Research Experts to Newly Formed Immunology Advisory Board

Retrieved on: 
星期三, 十二月 7, 2022
Health, Infectious Diseases, General Health, Research, Science, Pharmaceutical, Biotechnology, Tao, Vall, Helen, Immune-mediated inflammatory diseases, Federalisation of the European Union, Ephraim, COVID-19, University of Barcelona, Natural killer T cell, Teaching hospital, Phosphorylation, Virus, Bristol Myers Squibb, Partnership, American Cancer Society, Inflammation, University, Hospital, University School, Machine learning, National academy, EFIS, MD, Signal transduction, Howard Hughes Medical Institute, Science, DNS, University of California, San Francisco, Faculty, Immunology, Homeostasis, Immune system, Microbiota, International Union of Immunological Societies, Patient, Immunotherapy, Research, Journal, Tyrosine, UCSF, IMID, Biomedical sciences, Long, DN Capital, Nicholas J. Pritzker, Pharmaceutical industry, Medical device, Biotechnology, Microbiology, Rheumatology

Members of the IMIDomics Immunology Advisory Board include:

Key Points: 
  • Members of the IMIDomics Immunology Advisory Board include:
    Andr Veillette, M.D.
  • Dr. Veillete is a member of the COVID-19 Vaccine Task Force and the Long COVID Task Force of the Government of Canada.
  • He serves on multiple academic and industry advisory boards and the Pfizer Board of Directors.
  • His research group studies Natural Killer cells, which recognize and eliminate cells that have become transformed or infected by viruses.

Disarming the immune system's lethal lung response

Retrieved on: 
星期五, 九月 23, 2022
Neuroscience, Inflammation, COVID-19, Ageing, Biomedical Research, Sepsis, Neutrophil, Nobel Prize, Neurodegeneration, Mouse, Environment, Infection, Signal transduction, Cancer, Cold, Blood, Protein, Weapon, Student, Hyperkinesia, Cold Spring Harbor Laboratory, Cell, Laboratory, SPRING, Tissue, Transfusion-related acute lung injury, Research, CSHL, Multimedia, Proning, Education, Disease, Death, PTP, Pharmaceutical industry, Vaccine, PTP1B

Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.

Key Points: 
  • Lung tissue is saturated with blood vessels, making them very susceptible to neutrophil attacks.
  • If severe enough, acute lung injuries can lead to acute respiratory distress syndrome (ARDS), the leading cause of death due to COVID-19.
  • Nicholas Tonks , Caryl Boies professor of cancer research at Cold Spring Harbor Laboratory (CSHL), and his team have found a drug candidate that can prevent lethal lung inflammation in mice by inhibiting a protein called PTP1B.
  • "When you think about COVID-19, acute lung injury and ARDS underlie the fatal aspects of the disease," Tonks says.

Global ANCA Vasculitis Drug Pipeline Market Research Report 2022 Featuring GSK, AstraZeneca, Staidson Biopharmaceuticals, Bristol-Myers Squibb, InflaRx, Chia Tai Tianqing Pharmaceutical & Visterra - ResearchAndMarkets.com

Retrieved on: 
星期四, 八月 25, 2022
Health, Pharmaceutical, AstraZeneca, Eosinophilic granulomatosis with polyangiitis, NDA, II, Technology, Benralizumab, Asthma, Survival, Awareness, Macrophage, Disease, Signal transduction, Basophil, Vasculitis, MedImmune, GlaxoSmithKline, ANCA, FDA, Therapy, Eosinophil, News, III, Clinical trial, Immunoglobulin G, Microscopic polyangiitis, Acquisition, Discovery, Patient, Pharmaceutical industry

The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global ANCA Vasculitis - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "ANCA Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape.
  • A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines.
  • The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development.

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Retrieved on: 
星期二, 八月 2, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Conditional sentence, IBD, Autoimmune disease, Inflammation, Psoriasis, CEO, IFN, Cardiovascular disease, Inflammatory bowel disease, Signal transduction, Cancer, Quality of life, Clinical trial, Patient, Lupus, Degenerative disease, TYK2, Autoimmunity, HKEX, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.
  • ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor being developed for the treatment of autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).
  • Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, ICP-488 is our third drug candidate entering into the clinic in the field of autoimmune disease.
  • We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.